Sarennya Pathmanandavel

¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing¹⁷⁷Lu-PSMA-I&T Therapy

Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker et al. · Journal of Nuclear Medicine · 2022 · 70 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Evaluation of¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho et al. · Journal of Nuclear Medicine · 2022 · 60 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

¹⁷⁷Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

Sarennya Pathmanandavel, Megan Crumbaker, Andrew O. Yam et al. · Journal of Nuclear Medicine · 2021 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

Louise Emmett, Nikeith John, Sarennya Pathmanandavel et al. · Therapeutic Advances in Medical Oncology · 2023 · 39 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)

Megan Crumbaker, Sarennya Pathmanandavel, Andrew O. Yam et al. · European Urology Oncology · 2020 · 38 citations

Medicine, Oncology, Urology +16